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EcoNomIc EvaluatIoNs IN INfEctIous dIsEasE: whIch INfEctIoNs, what 
sEttINgs aNd what tyPE of EcoNomIc EvaluatIoNs wErE rEPortEd IN 
PaPErs PublIshEd IN 2014?
Martin A
Crystallise Ltd., London, UK
Objectives: To determine the focus of economic evaluation papers relevant to 
infectious diseases that were indexed in the PubMed database and published in 
2014. MethOds: An evidence surveillance process was established based on a 
systematic search of PubMed, using key words relevant to economic modelling in 
healthcare or disease and limited to studies published in English, in humans, and 
with abstracts. Articles were included if they analysed the cost-effectiveness of 
interventions, healthcare service design or methodological issues related to one 
or more infectious disease. We included all studies with a publication date of 2014 
that were indexed in PubMed up to 8 June 2015. Results: The search identified 
2,772 articles published in 2014. Of these, 148 were conducted in patients with 
infectious diseases. Most (32 articles) were in HIV-infected people, 14 articles were 
in those with hepatitis C, 13 in tuberculosis, 9 in human papilloma virus infec-
tion, 7 in pneumonia, and 6 each in influenza and hepatitis B. Twenty-five analyses 
were set in African countries, mainly on HIV (11 articles) and malaria (4). The 24 
analyses in Asia were more diverse, with only 3 each on HIV and tuberculosis. 
The 30 European analyses were also diverse, with 5 on hepatitis C, 4 each on HIV 
and pneumonia, and 3 on hospital-acquired infections. Of the 35 North American 
analyses, 8 related to hospital-acquired infections, 6 to hepatitis C, 4 to hepatitis 
B, and only 2 each on HIV or tuberculosis. Cost-utility analyses were reported in 
58 articles and cost-effectiveness in 43, and only 11 abstracts stated that indirect 
costs were modelled. cOnclusiOns: Infectious diseases were the most common 
disease class to be evaluated for cost-effectiveness in our search for studies pub-
lished in 2014, with a geographical focus that reflects the relevant epidemiology. 
Despite potential societal costs from pandemics or chronic infection, evaluations 
rarely considered indirect costs.
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PharmacoEPIdEmIologIc modElINg of trEatmENt hIv-INfEctEd 
PatIENts wIth rIlPIvIrINE/ tENofovIr/ EmtrIcItabIN (sINglE tablEt 
rEgImEN) IN russIa
Yagudina R, Kulikov A, Babiy VV,
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To obtain potential pharmacoepidemiologic outcomes of rilpivirine/ 
tenofovir/ emtricitabin (single tablet regimen) in treatment of naïve patients with 
HIV-1 RNA< 100 000 copies/ml in the Russian Federation. MethOds: The developed 
model was by nature a mathematical one. It was based on published data from 
international researches (efficacy data), from local researches in Eastern Europe 
(data on probability of death and disease progression, sexual behavior), and from 
researches in the Russian Federation (data on HIV-infected patient population, life 
expectancy etc.). The model included analysis of viral transmission via sexual con-
tact and/or injection drug use. The influence of character of sexual contact, condom 
effectiveness and efficacy of three schemes of highly active antiretroviral treat-
ment was taken into account. The time-horizon was 5 years. Results: Treatment of 
naïve HIV-infected patients with rilpivirine/ tenofovir/ emtricitabin leads to poten-
tial smaller number of new infected persons in long term perspective than with 
efavirenz + tenofovir/ emtricitabin (multi-pill regimen) and lopinavir + tenofovir/ 
emtricitabin (multi-pill regimen) by a term of order 13% (9570 new HIV-patients 
less) and 10% (7262 new HIV-patients less), respectively. cOnclusiOns: Obtained 
results approves the use of rilpivirine/ tenofovir/ emtricitabin (single tablet regimen) 
in similar to analyzed patient populations due to the potential lower number of new 
HIV-patients as compared to multi-pill regimens: efavirenz + tenofovir/ emtricitabin 
and lopinavir + tenofovir/ emtricitabin.
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thE EPIdEmIologIcal aNd cost burdEN of hErPEs ZostEr (hZ) aNd Post-
hErPEtIc NEuralgIa (PhN) IN thE uk
Taieb V1, Schwarzbard J1, Butt T2, Gama J2, Gauthier A1, Gallagher E2
1Amaris, London, UK, 2Sanofi Pasteur MSD, Maidenhead, UK
Objectives: This retrospective database analysis aimed to update epidemiologi-
cal and cost estimates related to HZ and PHN in adults from the perspective of 
the UK National Health Service (NHS). MethOds: Adults (18+) diagnosed with HZ 
between 2006 and 2013 were identified from The Health Improvement Network 
(THIN) linked to the Hospital Episode Statistics (HES) database. Unit costs were 
assigned from the British National Formulary, PSSRU Unit Costs of Health and 
Social Care and NHS Payment Grouper. Results: 27,362 patients with HZ were 
identified, corresponding to an incidence of 4.12% in the adult population. Average 
age at HZ diagnosis was 60.4. 137,674 HZ cases occurred in immunocompetent 
patients aged 50 or more. 21% of HZ patients developed PHN at least 3 months 
after HZ diagnosis. The mean duration of PHN was 13 months. In the first month 
of diagnosis, the mean cost of HZ per patient was £65.5 (61% visits, 29% medica-
tions, 10% hospitalisations). The mean cost of PHN per patient was £921 (63% visits, 
37% medications and less than 1% hospitalisations), the mean monthly cost was 
£58.7. The total cost associated with incident cases of HZ and PHN over a year 
was estimated at £52,543,827 in the UK. PHN was the most important driver of 
cost (72% of total). cOnclusiOns: This study re-affirms the significant burden 
of HZ and PHN on the UK health care system and shows that the mean age of HZ 
onset is significantly lower than current recommended age for HZ vaccination.
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PublIc hEalth aNd EcoNomIc bENEfIts of QuadrIvalENt INfluENZa 
vaccINE IN PaNama
Jamotte A1, Caicedo Navas AG2, Macabeo B3, Lopez JG4, Moreno B5, Franco D5, Garcia LN6, 
Isaza de Molto Y6
from SPRING-2, SINGLE and FLAMINGO trials, each one of them went through a 
Markov chain to emulate each patient life from initial treatment to death. The 
health states included were: living with HIV with or without opportunistic infec-
tions, long-term chronic diseases and death. Transition probabilities for each 
1-month cycle, were obtained from clinical trials. Utilities and direct health-care 
costs (€ 2015) were obtained from literature and national databases. A 3% annual 
discount was applied to costs and health outcomes. Sensitivity analysis with 0% 
and 5% discount rates were performed. Results: Treatment initiation with DTG/
ABC/3TC was dominant when it was compared with treatment initiation with all 
the comparators: vs. FTC/TDF/EFV (-67,210.71€ /QALY), vs. DRV/r + FTC/TDF or 
ABC/3TC (-152,411.73€ /QALY), and vs. RAL + FTC/TDF or ABC/3TC (-182,480.19€ /
QALY). All the sensitivity analyses performed showed the consistency of these 
findings. The main driver of cost was ATR-treatment (about 80%) followed by the 
costs of care (around 14%). cOnclusiOns: With the premises considered, treat-
ment initiation with DTG/ABC/3TC STR appears to be the most cost-effective 
option in ART-naïve HIV infected patients from the Spanish Health System per-
spective.
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cost-EffEctIvENEss of lEdIPasvIr/sofosbuvIr for thE trEatmENt of 
gENotyPE 1 or 4 chroNIc hEPatItIs c IN ENglaNd aNd walEs
Howells R1, Treharne C2
1Abacus International, Manchester, UK, 2Abacus International, Bicester, UK
Objectives: Ledipasvir/sofosbuvir (LDV/SOF; Harvoni) is a new oral single table 
regimen for the treatment of chronic hepatitis C (CHC) in adults. This study 
assessed the cost-effectiveness of LDV/SOF compared to current treatment options 
and ‘no treatment’ in England and Wales. MethOds: A Markov model with a 
lifetime horizon was constructed in Microsoft Excel® to assess cost-effectiveness 
of LDV/SOF. Cost-effectiveness was assessed separately for treatment-naïve (TN) 
and experienced (TE) patients with CHC genotype 1 (GT1) or 4 (GT4). Cycle lengths 
were monthly (first 18 cycles), three-monthly (until year 2), and yearly (year 3 
onwards; half-cycle correction applied from year 3). Costs and utilities were dis-
counted at 3.5%; data were sourced from published literature. Patients could enter 
the model in a non-cirrhotic or cirrhotic disease state. For each cycle, patients 
remained in their current health state, achieved a sustained virological response 
(equivalent to a cure), progressed to more severe disease or died. General popu-
lation mortality was applied in each health state. An excess mortality risk was 
associated with advanced liver disease (decompensated cirrhosis, hepatocellular 
carcinoma, and liver transplantation). Cost-effectiveness was assessed using the 
incremental cost-effectiveness ratio (ICER), expressed as cost per quality adjusted 
life year (QALY). Results: In GT1 TN patients without cirrhosis (8 weeks LDV/SOF 
treatment) and GT4 TN patients without cirrhosis (12 weeks LDV/SOF treatment), 
LDV/SOF was cost-effective for all comparators with ICERs of £8,894 and £22,676 
versus the next most effective non-dominated option, respectively. In GT1 or GT4 
TN patients with cirrhosis, TE patients without cirrhosis, and TE patients with 
cirrhosis, 12 week LDV/SOF was associated with ICERs of £4,518, £16,566, and 
£5,435 versus no treatment, respectively; all active comparators were dominated 
or extendedly dominated. cOnclusiOns: LDV/SOF represents a cost-effective 
option versus established practice for GT1 and GT4 TN and TE patients with and 
without cirrhosis.
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tEstINg for Ns5a rEsIstaNcE IN ordEr to oPtImIZE aNtIvIral thEraPy 
wIth sImEPrEvIr aNd sofosbuvIr 12 wEEks aPPEars cost-EffEctIvE IN 
NoN-cIrrhotIc gENotyPE 1 hEPatItIs c vIrus trEatmENt ExPErIENcEd 
PatIENts
Westerhout KY1, Bouwmeester W1, Duchesne I2, Sbarigia U3, Pisini M2, Treur M1
1Pharmerit International, Rotterdam, The Netherlands, 2Janssen EMEA, Beerse, Belgium, 3Janssen 
Global Services, Beerse, Belgium
Objectives: Sustained virologic response (SVR) of NS5A inhibitor-containing 
regimens is reduced in genotype-1 hepatitis C virus (HCV) patients with NS5A 
resistance. The long-term persistence of NS5A resistance limits re-treatment 
options (Wyles et al, 2015). Latest EASL treatment guidelines recommend 
simeprevir+sofosbuvir with/without ribavirin (SMV+SOF±R) for re-treating 
patients failing a NS5A inhibitor-containing regimen. This study investigates 
the cost-effectiveness of NS5A resistance-testing (before treatment) to optimize 
treatment choice and avoid the need for re-treatment. MethOds: An existing 
lifetime Markov model was used to estimate disease progression for HCV genotype 
1 patients in the UK. Patient subgroups were identified by cirrhosis stage and prior 
treatment experience. NS5A resistance-testing pre-treatment and subsequent 
treatment with SMV+SOF or sofosbuvir+ledipasvir (SOF+LDV±R) in patients with 
or without NS5A resistance, respectively, was compared to a ‘no testing’ scenario 
where all patients received SOF+LDV±R. SVR rates of SOF+LDV±R in patients with/
without NS5A resistance were obtained from pooled phase II/III studies. SMV+SOF 
SVR rates, not impacted by NS5A resistance, were sourced from the OPTIMIST 
studies. Patient characteristics, HCV progression, mortality, resource utilization, 
unit costs and quality of life data were obtained from published sources. Results: 
Testing for NS5A and optimizing therapy to SMV+SOF (for patients with NS5A 
resistance pre-treatment) yielded 0.127 additional QALYs and increased costs 
with ~£2000 per patient (both 3.5% discounted), resulting in an incremental cost-
effectiveness ratio (ICER) of ~£15K versus ‘no testing’ in treatment experienced 
patients without cirrhosis. In these non-cirrhotic patients, optimizing therapy 
to receive 24 weeks of SOF+LDV±R in NS5A positive patients led to an ICER of 
> 100K compared to optimizing with 12 weeks of SMV+SOF. cOnclusiOns: 
NS5A resistance testing pre-treatment and subsequent optimizing therapy 
with SMV+SOF 12 weeks instead of SOF+LDV±R 12 weeks appeared to be 
cost-effective in treatment-experienced HCV patients without cirrhosis and 
with NS5A resistance. Optimizing with SOF+LDV±R 24 weeks was not deemed 
cost-effective.
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8 in 10 HIV positive patients’ lost-to-follow up adhere to ART. Interventions such 
as comprehensive HIV training targeting health worker attitudes and perceptions 
of HIV positive patients such as pre- and post HIV test counseling may further 
improve ART adherence.
PIN83
ExPlorINg attItudEs aNd PErcEPtIoNs of PatIENts aNd staff towards 
a fEE for sErvIcE “aftEr hours” clINIc suPPlEmENtINg frEE hIv 
sErvIcEs IN ugaNda: a QualItatIvE study
Adelline T1, King R2, Schlech WF3, Faridah M1, Kakaire T1, Rosalind Parkes-Ratanshi P1
1Infectious Diseases Institute, College of Health Sciences Makerere University.re, Kampala, 
Uganda, 2University of California, San Francisco, San Francisco, CA, USA, 3Dalhousie University, 
Nova Scotia, NS, Canada
Objectives: The scale up of HIV services and access to anti-retroviral therapy in 
Africa has been made possible in the last 10 years. However, it is important that 
more sustainable “in country” options are explored for sustainability of services. 
The adult HIV clinic at the Infectious Diseases Institute (IDI) in Kampala, Uganda 
has approximately 8000 registered patients who receive care free of charge. We are 
exploring the possibility that some patients are willing /able to contribute to the 
cost of their care. Our objective was to explore attitudes and perceptions of patients 
and staff towards using a fee-based “after hours” clinic (AHC) at IDI. MethOds: We 
employed a cross-sectional, qualitative design. A purposeful sample of 188 adults 
which included current HIV clients and IDI staff was stratified by gender and age. We 
conducted 14 focus group discussions and 55in-depth interviews. Thematic content 
analysis was conducted and Nvivo Software used to manage data. Results: There 
were six key themes that emerged regarding participant perceptions of the AHC. 
Access to care (positive and negative), benefits and disadvantages of an AHC, key 
categories of health care services, recommending the service to friends, sliding scale 
fee-for-service, and suggestions to improve service delivery. Results suggested that 
some respondents were willing to pay for consultation, brand-name drugs, lab tests 
and other services. All were willing to recommend friends/ relatives. Respondents 
agreed that, as a sign of social responsibility, some money could be used to help 
underprivileged patients cOnclusiOns: Our AHC clinic is perceived as beneficial 
to patients because it provides access to HIV services at convenient times. Many 
patients are willing to pay for this enhanced service. Promotion of quality private-
public partnerships aiming to sustain quality HIV services in Uganda should be 
encouraged.
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hEalth statE utIlItIEs of rIsks assocIatEd wIth aNtIrEtrovIral 
trEatmENt for humaN ImmuNodEfIcIENcy vIrus (hIv)
Matza LS1, Chung KC2, Kim KJ1, Paulus T3, Davies EW4, Stewart KD1, McComsey GA5, 
Fordyce M2
1Evidera, Bethesda, MD, USA, 2Gilead Sciences, Inc, Foster City, CA, USA, 3University of Georgia, 
Athens, GA, USA, 4Evidera, London, UK, 5Case Western Reserve University, Cleveland, OH, USA
Objectives: People with human immunodeficiency virus (HIV) have increased risk 
of cardiovascular disease (CVD), kidney disease, and low bone mineral density. Some 
antiretroviral therapies (ART) further increase the risk of these events. The purpose of 
this study was to estimate health state utilities associated with these risks so that the 
values may be used in cost-utility models. MethOds: Qualitative thematic analysis 
was conducted to examine 4,122 messages posted to the POZ/AIDSmeds Internet 
Community Forums from 2008 to 2014. This analysis assessed member awareness of, 
concerns about, and treatment changes due to bone, kidney, and heart-related side 
effects and risks of HIV/AIDS medications. Then, health state vignettes were drafted 
based on this qualitative analysis, literature review, and clinician interviews. The 
health states (representing HIV, plus treatment-related risks) were valued in time 
trade-off (TTO) interviews with general population participants in the UK (London, 
Edinburgh). Results: Quantitative analysis of the Internet forums documented 
patient concerns about ART risks, as well as treatment decisions made because of 
these risks. A total of 208 participants completed utility interviews (51.4% female; 
mean age 44.6y). The mean (SD) utility of the basic HIV health state (describing a viro-
logically suppressed patient treated with ART) was 0.86 (0.14). Adding a description 
of risk to this basic health state was associated with statistically significant disutility 
(i.e., utility decreases): risk of renal problems (disutility = -0.02), risk of bone problems 
(-0.03), and risk of myocardial infarction (-0.05). Health states including the medical 
conditions themselves, rather than risk, had larger disutilities (e.g., stage 4 chronic 
kidney disease; disutility = -0.19). cOnclusiOns: The vignette-based TTO method 
was feasible for quantifying the utility impact of ART-related risks, demonstrating 
small but consistent disutilities. These disutilities may be used in cost-utility models 
comparing the value of treatments for patients with HIV.
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dIsutIlItIEs assocIatEd wIth cENtral NErvous systEm (cNs) sIdE 
EffEcts of aNtIrEtrovIral thEraPy (art) IN hIv
Gallop K1, Acaster S1, Nafees B2, Rogatto F3, Reilly G3, Perard R3
1Acaster Consulting Ltd, London, UK, 2Nafees Consulting, London, UK, 3Gilead Sciences Europe 
Ltd, Uxbridge, UK
Objectives: The introduction of effective ART in HIV has led to substantial reduc-
tions in morbidity and mortality. However adverse events (AEs) associated with ARTs 
can lead to discontinuation, and worsening of health-related quality of life (HRQL). 
This study aimed to elicit societal disutility values for CNS side effects associated 
with ARTs in France. MethOds: Health states (HS) were developed from interviews 
with HIV patients (N= 9) and one specialist clinician in France. HS were developed to 
describe a stable HIV health state (on treatment), and nine CNS side effects associated 
with ARTs (abnormal dreams, insomnia, anxiety and depression, suicidal thoughts, 
balance and coordination problems, attention difficulties, dizziness, headaches and 
somnolence). Draft HS were reviewed and refined in interviews with patients and 
clinicians (N= 4 in total). The revised HS were piloted with general public to check 
understanding and then evaluated by 100 members of the public in France using 
1Creativ-Ceutical, Paris, France, 2Sanofi Pasteur, Bogota, Colombia, 3Sanofi Pasteur, Lyon, France, 
4Sanofi Pasteur, Mexico City, Mexico, 5Gorgas Memorial Institute for Health Studies, Panama City, 
Panama, 6Panama Ministry of Health, Panama City, Panama
Objectives: Annual trivalent influenza vaccines (TIV) containing three influenza 
strains (A/H1N1, A/H3N2, and one B) have been recommended in Panama since 2006. 
However, worldwide co-circulation of two distinct B lineages (Victoria and Yamagata) 
and difficulties in predicting which lineage will predominate in the next season have 
led to the development of quadrivalent influenza vaccines (QIV) including both B 
lineages. Our analysis evaluates the public health and economic benefits of using 
QIV versus TIV in Panama from 2006 to 2013. MethOds: A static model published 
by Reed et al. in 2012 was adapted to Panama and stratified by age group. In addition, 
B-lineage cross-protection was included based on published sources. We calculated 
the hypothetical impact of QIV compared with TIV over seven influenza seasons 
(2009 pandemic year excluded) using virologic circulation, vaccine coverage, vaccine 
effectiveness and attack rate. In absence of B-lineage distribution in Panama, Brazilian 
data were considered. For influenza-related outcomes (outpatient visits, hospitalisa-
tions, deaths), two sets of inputs were used. Influenza-related costs were estimated 
from societal perspective in Panamanian balboas (1 per US dollar). Results: Over 
the 2006-2013 period, QIV would have prevented 7,519 influenza B cases compared 
with TIV, averting between 2,756 and 5,564 outpatients visits, between 28 and 2,202 
hospitalisations and between 6 and 930 deaths. This translates into influenza-related 
avoided costs of between 137 and 3,599 thousand balboas. In 2012, year with high 
B circulation and mismatch, QIV would have avoided 5,256 cases, 3,889 outpatient 
visits, 1,539 hospitalisations, 650 deaths and 2.5 million balboas of influenza-related 
costs in the upper bound. cOnclusiOns: The wider protection offered by QIV would 
reduce the number of influenza infections and its related complications, leading to 
influenza-related costs avoided. Herd effect was not taken into account, underesti-
mating the benefits of QIV vaccination. More robust local data are needed to better 
assess benefits of QIV.
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PublIc hEalth aNd EcoNomIc bENEfIts of QuadrIvalENt INfluENZa 
vaccINE IN colombIa
Jamotte A1, Caicedo Navas AG2, Macabeo B3, Lopez JG4, Romero M5, Marrugo R5, Alfonso 
Quiñones PA5
1Creativ-Ceutical, Paris, France, 2Sanofi Pasteur, Bogota, Colombia, 3Sanofi Pasteur, Lyon, France, 
4Sanofi Pasteur, Mexico City, Mexico, 5Salutia Foundation, Bogotá, Colombia
Objectives: Annual trivalent influenza vaccines (TIV) containing three influenza 
strains (A/H1N1, A/H3N2, and one B) have been recommended in Colombia since 
2007. However, worldwide co-circulation of two distinct B lineages (Victoria and 
Yamagata) and difficulties in predicting which lineage will predominate in the 
next season have led to the development of quadrivalent influenza vaccines (QIV) 
including both B lineages. Our analysis evaluates the public health and economic 
benefits of using QIV versus TIV in Colombia from 2007 to 2014. MethOds: A 
static model published by Reed et al. in 2012 was adapted to Colombia and strati-
fied by age group. In addition, B-lineage cross-protection was included based on 
published sources. We calculated the hypothetical impact of QIV compared with 
TIV over seven influenza seasons (2009 pandemic year excluded) using virologic 
circulation, vaccine coverage, vaccine effectiveness and attack rate. In absence of 
B-lineage distribution in Colombia for 2007-2013, Brazilian data were considered. 
For influenza-related outcomes (outpatient visits, hospitalisations, deaths), two 
input sets were used. Influenza-related costs were estimated from societal per-
spective in Colombian pesos (0.00052 per US dollar in 2013). Results: Over the 
2007-2014 period, QIV would have prevented 27,957 influenza B cases compared 
with TIV, averting between 10,450 and 19,188 outpatient visits, between 492-7,549 
hospitalisations and between 31-2,028 deaths. This translates into influenza-related 
avoided costs of between 1.7 and 12.5 billion pesos. In 2014, year with high B circula-
tion and mismatch, QIV would have avoided 14,771 cases, 10,138 outpatient visits, 
3,989 hospitalisations, 1,071 deaths and 6.6 billion pesos of influenza-related costs 
in the upper bound. cOnclusiOns: The wider protection offered by QIV would 
reduce the number of influenza infections and its related complications, leading 
to influenza-related costs avoided. Herd effect was not taken into account, under-
estimating the benefits of QIV vaccination. More robust local data are needed to 
better assess benefits of QIV.
INfEctIoN – Patient-reported outcomes & Patient Preference studies
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adhErENcE to aNtIrEtrovIral thEraPy amoNg PatIENts lost-to-
follow uP: a casE of aN hIv clINIc IN a PrIvatE-for-ProfIt hEalth 
facIlIty IN kamPala, ugaNda
Anguzu R, Turyagyenda F
Makerere University School of Public Health, Kampala, Uganda
Objectives: To determine the level of adherence to ART among HIV positive 
patients lost-to-follow in an HIV clinic in a private-for-profit health facility in 
Kampala district, Uganda. MethOds: A cross-sectional study design was con-
ducted in an HIV clinic in Kampala district. Medical records of 550 HIV positive 
attending the HIV clinic from April 2005 to April 2012 in a private-for-profit health 
facility were analyzed. Per ART dataset, 147 HIV positive patients were identified as 
being lost-to-follow up to HIV care among which 94 were accessible for interviews. 
Loss-to-follow up was regarded as HIV positive patients who had not attended 
ART clinic for a period or 4 or more months. A telephone interview was conducted 
using a pretested structured questionnaire in order to assess adherence to ART and 
factors associated with loss to follow up from the ART clinic. Results: The level of 
adherence to ART was 77.7% while level of loss to follow up was 26.7%. Predictors of 
adherence to ART were; distance from health facility (AOR = 0.01, 95% CI = 0.00-0.35), 
health worker attitude (AOR = 9.43, 95% CI = 1.55 – 57.43) and patients perception of 
lifetime ART medication (AOR = 26.54, 95% CI = 3.33 – 211.2) cOnclusiOns: About 
